Cannabis company AusCann Group
(ASX:AC8) has advanced the development of cannabinoid hard shell capsules.
They signed an agreement with PCI Pharma for the manufacture.
As they released their overview of their activities for the three months ending December 2018 they also showed that AusCann is on track for the production of cannabinoid medicines for use in clinical trials during this calendar year.
These medicines will be taken through the Company’s clinical development program for registration as an approved medical cannabis pain management pharmaceutical product.
The capsules will be targeted for sufferers of chronic and neuropathic pain, which in Australia alone account for 1.9 million people.
Shares in AusCann Group
(ASX:AC8) are trading 1.55 per cent higher to 66 cents.
